Taysha Gene Therapies (TSHA) Misses Q2 EPS by 7c, beats revenue

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.38), $0.07 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $2.1 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
• Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings